Transfusion‐transmitted CMV infection – current knowledge and future perspectives

摘要: Transmission of human cytomegalovirus (CMV) via transfusion (TT-CMV) may still occur and remains a challenge in the treatment immunocompromised CMV-seronegative patients, e.g. after stem cell transplantation, for low birthweight infants. Measures to reduce risk TT-CMV have been evaluated clinical studies, including leucocyte depletion cellular blood products and/or selection CMV-IgG-negative donations. Studies large donor cohorts indicate that donations from newly CMV-IgG-positive donors should bear highest transmitting CMV infections because they contain levels CMV-DNA, early antibodies cannot neutralise CMV. Based on this knowledge, rational strategies residual using leucoreduced could be designed. However, there is lack evidence transmitted by units. In infants, most (if not all) are caused breast milk feeding or congenital transmission rather than products. For other patients at risk, no definitive data exist about relative importance alternative routes compared transfusion. As result, only conduction well-designed studies addressing prevent thorough examination presumed cases will achieve guidance best regimen risk.